Compare Novartis with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SHASUN PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SHASUN PHARMA NOVARTIS/
SHASUN PHARMA
 
P/E (TTM) x 900.6 123.9 726.8% View Chart
P/BV x 27.1 8.5 317.3% View Chart
Dividend Yield % 1.6 0.2 699.7%  

Financials

 NOVARTIS   SHASUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
SHASUN PHARMA
Mar-14
NOVARTIS/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs98094 1,040.3%   
Low Rs60046 1,316.2%   
Sales per share (Unadj.) Rs198.7214.2 92.8%  
Earnings per share (Unadj.) Rs21.05.3 393.0%  
Cash flow per share (Unadj.) Rs22.315.8 140.7%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.31.4 88.5%  
Book value per share (Unadj.) Rs307.553.3 576.5%  
Shares outstanding (eoy) m24.6956.62 43.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.00.3 1,218.2%   
Avg P/E ratio x37.713.1 287.6%  
P/CF ratio (eoy) x35.54.4 803.5%  
Price / Book Value ratio x2.61.3 196.1%  
Dividend payout %47.718.7 254.5%   
Avg Mkt Cap Rs m19,5083,958 492.9%   
No. of employees `0000.6NA-   
Total wages/salary Rs m1,1712,164 54.1%   
Avg. sales/employee Rs Th8,445.4NM-  
Avg. wages/employee Rs Th2,015.7NM-  
Avg. net profit/employee Rs Th891.0NM-  
INCOME DATA
Net Sales Rs m4,90712,127 40.5%  
Other income Rs m783229 341.2%   
Total revenues Rs m5,68912,356 46.0%   
Gross profit Rs m1231,009 12.2%  
Depreciation Rs m32594 5.4%   
Interest Rs m16415 3.8%   
Profit before tax Rs m858230 373.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m340-73 -467.5%   
Profit after tax Rs m518302 171.4%  
Gross profit margin %2.58.3 30.1%  
Effective tax rate %39.6-31.7 -125.2%   
Net profit margin %10.62.5 423.5%  
BALANCE SHEET DATA
Current assets Rs m8,0556,884 117.0%   
Current liabilities Rs m1,8508,456 21.9%   
Net working cap to sales %126.4-13.0 -975.7%  
Current ratio x4.40.8 534.7%  
Inventory Days Days4562 73.0%  
Debtors Days Days34108 31.5%  
Net fixed assets Rs m1504,970 3.0%   
Share capital Rs m123113 108.9%   
"Free" reserves Rs m7,4692,875 259.8%   
Net worth Rs m7,5923,020 251.4%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m9,82413,347 73.6%  
Interest coverage x54.91.6 3,537.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.9 55.0%   
Return on assets %5.45.4 101.1%  
Return on equity %6.810.0 68.2%  
Return on capital %11.513.3 86.4%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m585,843 1.0%   
Fx outflow Rs m1,3262,173 61.0%   
Net fx Rs m-1,2693,669 -34.6%   
CASH FLOW
From Operations Rs m-1,943398 -488.6%  
From Investments Rs m2,742-1,635 -167.7%  
From Financial Activity Rs m-2981,309 -22.8%  
Net Cashflow Rs m50171 704.1%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 3.6 55.6%  
FIIs % 1.6 17.6 9.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 39.6 54.3%  
Shareholders   41,647 20,750 200.7%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON   J.B.CHEMICALS  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Lower; Energy and Healthcare Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 25, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - SUN PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS